Evidence map›Paper›PMID 39702632›Full record

ArticleEuropean radiology2025

Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy.

Michel Dupuis, Axelle Dupont, Silvia Pizza, Valérie Vilgrain, Aurélie Bando Delaunay, Rachida Lebtahi, Mohamed Bouattour, Maxime Ronot, Jules Grégory

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michel DupuisDepartment of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Axelle DupontClinical Research, Biostatistics and Epidemiology Department, AP-HP Nord-Université Paris Cité, HUPNVS, Paris, France.
Silvia PizzaDepartment of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Valérie VilgrainDepartment of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Aurélie Bando DelaunayDepartment of Nuclear Medicine, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Rachida LebtahiDepartment of Nuclear Medicine, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Mohamed BouattourLiver Cancer Unit, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Maxime RonotDepartment of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Jules GrégoryDepartment of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France. jules.gregory@aphp.fr.ORCID http://orcid.org/0000-0001-6081-1663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study evaluates the prognostic value of tumor response on CT at 3 months, assessed by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Liver Imaging Reporting and Data System Treatment Response Algorithm (LR-TRA) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT). MATERIALS AND

methodsA retrospective analysis was conducted on 102 HCC patients treated with SIRT between 2018 and 2020. RECIST, mRECIST, and LR-TRA were assessed at 3 months post-SIRT. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and Cox proportional-hazards models.

resultsThe median age was 71 years, and most patients (90%) had advanced-stage tumors (Barcelona Clinic Liver Cancer-C). After a median follow-up of 32.0 months (95% CI: 16.8-60.9), 60/102 patients died (59%), and 90/102 patients showed tumor progression (88%). Median OS was 20.4 months (95% CI: 15.4-33.0), and median PFS was 14.5 months (95% CI: 6.5-24.5); 1-year OS and PFS rates were 65.6% and 50.7%. Multivariable analysis revealed that early response according to RECIST 1.1 (HR 1.66, p = 0.30), mRECIST (HR 1.40, p = 0.215), and LR-TRA (HR 0.67, p = 0.30) were not predictors of OS. Disease progression evaluated by RECIST (HR 2.55, p < 0.001) and mRECIST (HR 2.53, p < 0.001), bilirubin levels (HR 1.03, p < 0.001), and prothrombin time (HR 0.98, p = 0.005) were predictors of OS. For PFS, neither RECIST nor mRECIST response, disease progression, nor LR-TRA viability were predictors.

conclusionIn this advanced-stage HCC population, early response assessed by RECIST, mRECIST, and LR-TRA criteria did not predict OS or PFS after SIRT. However, early disease progression and liver function indicators were prognostic factors for OS. KEY POINTS: QuestionHow well does early tumor response, assessed at 3 months post-selective internal radiation therapy (SIRT), predict survival in advanced hepatocellular carcinoma (HCC) patients? Findings Early response, assessed by RECIST, mRECIST, and LR-TRA, did not predict overall or progression-free survival; disease progression and liver function indicators were significant predictors. Clinical relevance This study highlights the limitations of early imaging criteria in predicting survival outcomes in advanced HCC post-SIRT, suggesting the need for alternative or complementary prognostic indicators to guide treatment decisions.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTomography, X-Ray ComputedAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisResponse Evaluation Criteria in Solid TumorsRetrospective StudiesTreatment OutcomeHepatocellular carcinomaLI-RADSSelective internal radiation therapyTrans-arterial radioembolizationTumor response

Identifiers

PMID39702632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.